Professor Michael Hofman is a nuclear medicine physician, physician-scientist and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at the Peter MacCallum Cancer Centre in Melbourne. He previously completed a research fellowship at Guy’s & St Thomas’ in London. He has broad research interest in radiopharmaceuticals for imaging and therapy (theranostics) in Oncology. This includes neuroendocrine tumours and hematologic applications; more recently he has focused on improving outcomes for men with prostate cancer. Prof Hofman has a leading academic track record for his specialty, with over 200 peer reviewed manuscripts and book chapters. He has received a number of international awards including the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Image of the Year 2018 and awards for best scientific research at several international conferences. He is a frequent invited speaker at national and international meetings, and was the co-chair of the scientific committee for the 4th World Theranostic World Congress in 2016. In 2015 he was elected a fellow of the International Cancer Imaging Society, one of three Australians recognized by the society. He was a member of the oncology subcommittee of the ongoing MBS Review where he advocates for fair and equitable access to PET scanning for patients with cancer.
TheraP/VISION Trial on Lutetium-PSMA
with Michael Hofman, MBBS, FRACP, FAANMS, FICIS, Director of the Prostate Cancer Theranostics and Imaging Center of Excellence (ProsTIC) at The Peter MacCallum Cancer Center in Melbourne, Australia.